LABT Stock Forecast: Lakewood-Amedex Biotherapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
LABT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Lakewood-Amedex Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (0): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Lakewood-Amedex Biotherapeutics, Inc. — and when they’d sell — is the membership.
LABT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LABT, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LABT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Lakewood-Amedex Biotherapeutics, Inc. (LABT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.7×
- Price / sales
- —
- Price / book
- −0.5×
- EV / EBITDA
- −0.8×
Cheaper than 81% of US stocks
Cheaper than 93% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 195.9%
- Return on assets
- −507.4%
- Dividend yield
- —
Higher than 98% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
LABT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| LABTLakewood-Amedex Biotherapeutics, Inc. | $3.5M | 23 |
| PPCBPropanc Biopharma, Inc. | $3.5M | 43 |
| REVBRevelation Biosciences, Inc. | $3.7M | 11 |
| ENSCEnsysce Biosciences, Inc. | $3.7M | 43 |
| XRTXXORTX Therapeutics, Inc. | $3.8M | 22 |
| ERNAErnexa Therapeutics, Inc. | $3.8M | 25 |
| CELZCreative Medical Technology Holdings, Inc. | $3.1M | 35 |
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LABT appears on the weeks it earns a place.
Frequently asked questions about LABT stock
How does Ticker Nerd's model rank LABT?
As at 1 Aug 2026, Lakewood-Amedex Biotherapeutics, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).
What is the LABT stock forecast for 2030?
No analyst covering Lakewood-Amedex Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LABT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
What does Lakewood-Amedex Biotherapeutics, Inc. do?
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials called Bisphosphocins to treat infectious diseases and combat antibiotic-resistant bacterial strains such as MRSA and VRE.
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials called Bisphosphocins to treat infectious diseases and combat antibiotic-resistant bacterial strains such as MRSA and VRE. The company's approach involves administering Bisphosphocins directly to infection sites, where they rapidly disrupt microbial cell membranes, leading to bacterial and fungal eradication within minutes. Lakewood-Amedex is advancing a gel formulation of Bisphosphocin Nu-3 into Phase 2 clinical trials for treating infected diabetic foot ulcers, while also developing treatments for bladder infections via catheter instillation and lung infections via inhalation. The company focuses on indications suitable for locally acting antimicrobials, positioning itself in the infectious disease and antimicrobial resistance markets. Based in Sarasota, Florida, Lakewood-Amedex Biotherapeutics began trading on the Nasdaq Capital Market in April 2026.
CEO Dr. Kelvin Cooper Ph.D. · 5 employees · United States · https://lakewoodamedex.com